Does anyone know why CS mentioned Msb from its analysis in Csl.
It said Msb's product is good for a transplant case.
"The equities team said highlights from the update included information on CSL's trials in the transplant therapeutics area, including treatments for graft-versus-host disease. Graft-versus-host disease is the immune response which can occur after an organ transplant, and is the problem that fellow biotech Mesoblast is trying to solve.Analysts also viewed the trial recruitment process for the company's heart attack drug CSL112 as a positive."
Phase 3 DREAM HF-1 read-out, page-30
-
- There are more pages in this discussion • 315 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 45345 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3875 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |